Cambridge Isotope Laboratories, Chemtatva announce Rs 300 crore joint venture in Telangana
Cambridge Isotope Laboratories and Chemtatva Chiral Solutions have announced a Rs 300 crore joint venture to set up advanced isotope manufacturing in Genome Valley, Telangana. The project is expected to create 250 high-skilled jobs and support pharmaceutical and semiconductor research.
Hyderabad: Cambridge Isotope Laboratories, Inc. (CIL), a global leader in stable isotope–labelled compounds, in collaboration with Hyderabad-based specialty chemicals manufacturer Chemtatva Chiral Solutions Pvt Ltd., has announced a strategic joint venture to establish advanced manufacturing capabilities in Telangana.
The joint venture plans to invest up to Rs 300 crore over the next three years in Genome Valley Phase 4, creating over 250 direct, high-skilled jobs and strengthening India’s position in manufacturing isotopically labelled molecules used in pharmaceutical research, diagnostics, advanced electronics, OLED materials, and semiconductor applications.
Dr Vishal Rajput, Founder & CEO of Chemtatva Chiral Solutions Pvt Ltd., said, “Over the past five years, Chemtatva has grown into a leading player in the stable isotopes space while creating more than 100 direct jobs.”
Cliff Caldwell, CEO, Cambridge Isotope Laboratories, said, “Through this collaboration with Chemtatva, we look forward to expanding our global manufacturing network and delivering high-quality isotopically labelled compounds to customers around the world.”
